Vinva Investment Management Ltd Increases Stock Position in Zimmer Biomet Holdings, Inc. $ZBH

Vinva Investment Management Ltd boosted its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 785.1% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 110,759 shares of the medical equipment provider’s stock after purchasing an additional 98,245 shares during the period. Vinva Investment Management Ltd’s holdings in Zimmer Biomet were worth $10,885,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Parallel Advisors LLC boosted its position in Zimmer Biomet by 43.4% in the 3rd quarter. Parallel Advisors LLC now owns 895 shares of the medical equipment provider’s stock valued at $88,000 after buying an additional 271 shares during the last quarter. Natixis Advisors LLC grew its stake in shares of Zimmer Biomet by 19.0% during the third quarter. Natixis Advisors LLC now owns 96,635 shares of the medical equipment provider’s stock valued at $9,519,000 after acquiring an additional 15,402 shares in the last quarter. Munich Reinsurance Co Stock Corp in Munich purchased a new stake in shares of Zimmer Biomet during the third quarter worth about $110,000. First Trust Advisors LP lifted its stake in shares of Zimmer Biomet by 62.6% in the third quarter. First Trust Advisors LP now owns 406,057 shares of the medical equipment provider’s stock worth $39,997,000 after acquiring an additional 156,388 shares in the last quarter. Finally, Legacy Capital Group California Inc. acquired a new position in shares of Zimmer Biomet in the third quarter worth about $216,000. Institutional investors and hedge funds own 88.89% of the company’s stock.

Wall Street Analyst Weigh In

ZBH has been the subject of a number of recent analyst reports. Sanford C. Bernstein raised their price objective on Zimmer Biomet from $97.00 to $99.00 and gave the company a “market perform” rating in a research note on Friday, January 9th. Barclays cut their target price on Zimmer Biomet from $104.00 to $100.00 and set an “underweight” rating on the stock in a research report on Thursday, February 12th. Canaccord Genuity Group reduced their target price on Zimmer Biomet from $101.00 to $93.00 and set a “hold” rating for the company in a research note on Monday, November 10th. Citigroup reissued a “buy” rating on shares of Zimmer Biomet in a research report on Wednesday, February 11th. Finally, Wells Fargo & Company lifted their price target on shares of Zimmer Biomet from $93.00 to $98.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 11th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, ten have issued a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $106.20.

Zimmer Biomet Stock Up 0.7%

ZBH stock opened at $94.08 on Monday. The firm has a market cap of $18.41 billion, a price-to-earnings ratio of 26.58, a PEG ratio of 1.92 and a beta of 0.58. Zimmer Biomet Holdings, Inc. has a 1-year low of $84.59 and a 1-year high of $114.44. The firm has a fifty day moving average price of $92.13 and a two-hundred day moving average price of $95.60. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.98 and a quick ratio of 1.10.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Tuesday, February 10th. The medical equipment provider reported $2.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.38 by $0.04. Zimmer Biomet had a net margin of 8.56% and a return on equity of 12.93%. The company had revenue of $2.24 billion for the quarter, compared to the consensus estimate of $2.22 billion. During the same period last year, the firm posted $2.31 EPS. The company’s revenue for the quarter was up 10.9% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. Research analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, April 30th. Shareholders of record on Tuesday, March 31st will be issued a $0.24 dividend. The ex-dividend date of this dividend is Tuesday, March 31st. This represents a $0.96 dividend on an annualized basis and a yield of 1.0%. Zimmer Biomet’s dividend payout ratio (DPR) is currently 27.12%.

Zimmer Biomet Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.